Zentalis Pharmaceuticals (NASDAQ:ZNTL) Rating Lowered to “Sell” at Wall Street Zen

Zentalis Pharmaceuticals (NASDAQ:ZNTL) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research report on Wednesday, October 8th. HC Wainwright raised Zentalis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 7th. Finally, Wells Fargo & Company lowered their target price on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $5.84.

Zentalis Pharmaceuticals Stock Performance

ZNTL opened at $1.28 on Friday. The stock has a market capitalization of $92.33 million, a price-to-earnings ratio of -0.57 and a beta of 1.87. Zentalis Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $4.44. The company has a fifty day moving average of $1.56 and a 200 day moving average of $1.45.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC grew its holdings in Zentalis Pharmaceuticals by 220.6% during the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after purchasing an additional 2,111,951 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Zentalis Pharmaceuticals by 150.6% during the first quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company’s stock valued at $4,244,000 after buying an additional 1,606,802 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of Zentalis Pharmaceuticals in the second quarter worth approximately $1,126,000. Tybourne Capital Management HK Ltd. raised its holdings in shares of Zentalis Pharmaceuticals by 53.7% in the second quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock worth $1,715,000 after buying an additional 516,666 shares during the period. Finally, Jane Street Group LLC lifted its stake in shares of Zentalis Pharmaceuticals by 346.3% during the 2nd quarter. Jane Street Group LLC now owns 664,061 shares of the company’s stock worth $770,000 after acquiring an additional 515,257 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.